ArticleDiscovery immunology2026
Human and porcine IgG subclasses differentially engage porcine Fc receptors.
Article in Discovery immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibody fragment crystallizable (Fc)-mediated effector functions and pharmacokinetics are governed by interactions between immunoglobulin G (IgG) subclasses and Fc gamma receptors (FcγRs) and Fc neonatal receptor (FcRn). Although pigs are increasingly used as translational models for therapeutic antibody evaluation, the interactions between porcine Fc receptors (pFcγRs) and porcine (pIgG) or human IgG (hIgG) subclasses remain poorly defined. Here, we characterized the interactions of pIgG and hIgG subclasses with pFcγRs and pFcRn and assessed their ability to mediate Fc-dependent effector functions in porcine immune cells. Using biolayer interferometry, we demonstrated subclass-dependent differences in receptor binding, driven primarily by dissociation kinetics. Porcine IgG2 and pIgG5c exhibited stable FcγR interactions, whereas pIgG3 and pIgG5b showed weak binding to several low-affinity receptors (FcγRIIa, FcγRIIb, and FcγRIIIa). Human IgG subclasses displayed distinct binding profiles to pFcγRs, with hIgG3 showing the strongest and hIgG2 the weakest binding affinity. Furthermore, hIgG1 and hIgG4 did not bind to pFcγRIIIa. Functional studies demonstrated that hIgGs mediate Fc-dependent phagocytosis and natural killer cell degranulation, although receptor-binding affinity did not always correlate with functional activity. Comparative phylogenetic and functional analyses further revealed that FcγR-binding phenotypes are only partially predicted by Fc domain sequence similarity. All pIgG and hIgG subclasses interacted with pFcRn in a comparable pH-dependent manner. These findings demonstrate substantial, but incomplete, conservation of Fc biology between humans and pigs. While supporting the use of pigs as a translational model for antibody pharmacokinetic studies, they also indicate the need for integrated biophysical, structural, and functional analyses before extrapolating Fc-mediated therapeutic activity between species.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.